---
title: "Victall released its performance for the first three quarters, with a net profit attributable to the parent company of 62.79 million yuan, a year-on-year increase of 447.61%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263079251.md"
description: "According to the Zhitong Finance APP, Victall disclosed its third-quarter report for 2025. The company achieved revenue of 1.252 billion yuan in the first three quarters, a year-on-year increase of 57.87%; net profit attributable to the parent company was 62.79 million yuan, a year-on-year increase of 447.61%; net profit excluding non-recurring gains and losses was 56.73 million yuan, a year-on-year increase of 581.63%; basic earnings per share were 0.16 yuan"
datetime: "2025-10-28T12:10:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263079251.md)
  - [en](https://longbridge.com/en/news/263079251.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263079251.md)
---

# Victall released its performance for the first three quarters, with a net profit attributable to the parent company of 62.79 million yuan, a year-on-year increase of 447.61%

According to the Zhitong Finance APP, Victall (605001.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 1.252 billion yuan in the first three quarters, a year-on-year increase of 57.87%; the net profit attributable to shareholders was 62.79 million yuan, a year-on-year increase of 447.61%; the net profit excluding non-recurring gains and losses was 56.73 million yuan, a year-on-year increase of 581.63%; the basic earnings per share were 0.16 yuan

### Related Stocks

- [605001.CN](https://longbridge.com/en/quote/605001.CN.md)

## Related News & Research

- [Obamacare Meltdown? Sharp ACA Enrollment Drop Expected As Pandemic-Era Subsidies End](https://longbridge.com/en/news/287067300.md)
- [BYD is struggling to meet demand for new fast-charging EVs as orders reach 100K, 60K](https://longbridge.com/en/news/287109883.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [Assessing BlueNord (OB:BNOR) Valuation After Its US$400 Million Refinancing Deal](https://longbridge.com/en/news/287098111.md)
- [Baby food from Ireland recalled due to potential mould growth and spoilage: SFA](https://longbridge.com/en/news/287093082.md)